GSK has announced that it will invest £275 million in its UK sites at Barnard Castle, in County Durham, Montrose in Scotland and Ware in Hertfordshire.

The money will go towards the company’s advanced manufacturing of new respiratory and biopharmaceuticals.

Andrew Witty, CEO of GSK said: “It is testament to our skilled UK workforce and the country’s leading position in life sciences that we are making these investments in advanced manufacturing here.”

Barnard Castle in County Durham is one of GSK’s biggest secondary manufacturing sites, employing 1,100 people. The site supplies nearly half a million packs of products per day to 140 global markets. The investment of £92 million will fund the construction of an aseptic sterile facility supporting the manufacture of existing and new biopharmaceutical assets in our pipeline.

Montrose in Angus in Scotland manufactures active ingredients for respiratory, HIV and vaccine products and employs more than 450 staff. The investment of £110 million will provide a new facility for the manufacture of respiratory active ingredients.

Ware in Hertfordshire, employs 1,200 staff, manufacturing innovative respiratory products. The investment of £74 million will support further expansion of the company’s new Ellipta respiratory inhaler through additional manufacturing capacity at the site.

GSK says that the announcement will support current employment at the sites and is expected to lead to the creation of jobs.